Interestingly, treatment with rosiglitazone, a Peroxisome proliferator-activated receptor gamma (PPAR-γ) agonist that increases adiponectin levels, improved survival in wild-type mice but failed to do so in adiponectin-deficient mice, reinforcing the crucial role of adiponectin in modulating the immune response and enhancing survival during sepsis [30]. Here, PPARG is linked to Sepsis.